Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being studied in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany in October 11-14, 2023.
|
[04-October-2023] |
TOKYO, Oct. 4, 2023 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being studied in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany in October 11-14, 2023. AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T cell-dependent inflammatory pathways; the relative contribution of different inflammatory pathways in driving disease can vary across populations and within individuals over time. Often beginning in childhood, AD affects 15-20% of children and up to 10% of adults, making it the 15th most common nonfatal disease. AD is prevalent in countries globally, with approximately 1 in 3 people with AD worldwide classifying their disease as moderate-to-severe. While treatment currently is available, there remains a need for additional therapeutic options with a novel mechanism of action to treat across a heterogeneous AD patient population. e-Poster Title: Rocatinlimab improves lichenification compared with placebo in adults with moderate-to-severe atopic dermatitis in a Phase 2b trial e-Poster Title: Rocatinlimab improves SCORAD compared with placebo in adults with moderate-to-severe atopic dermatitis regardless of baseline demographics in a Phase 2b trial e-Poster Title: Rocatinlimab improves SCORAD and DLQI in adults with moderate-to-severe atopic dermatitis and these effects were maintained in the 20-week off-treatment period in a double-blind randomized Phase 2b study About rocatinlimab It has been reported that effector T cells expressing OX40 are present in the lesions of patients with atopic dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology. Amgen and Kyowa Kirin Collaboration About Kyowa Kirin
SOURCE Kyowa Kirin |
||
Company Codes: Tokyo:4151, OTC-PINK:KYKOY |